Hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs)

被引:24
作者
de Weck, A. L.
Gamboa, P. M.
Esparza, R.
Sanz, M. L.
机构
[1] Univ Navarra, Univ Navarra Clin, Dept Allergol & Clin Immunol, E-31080 Pamplona, Spain
[2] Hosp Basurto, Div Allergol, Bilbao, Spain
关键词
aspirin; NSAID; hypersensitivity; basophils; LTC4; leukotriene release; flowcytometry;
D O I
10.2174/138161206778193971
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hypersensitivity to aspirin and other non steroidal anti-inflammatory drugs (NSAIDs) manifesting in the airways (rhinosinusitis, polyps, asthma) or in the skin (urticaria, angioedema) is the second most frequent untoward allergic reaction to drugs. Various aspects of this syndrome, such as its clinical features, the cell types and mediators involved, the role of underlying chronic inflammatory processes, the patterns of cross-reactivity between NSAIDs, the major role of sulfidoleukotrienes (LTC4) and of some other mediators such as prostaglandin E2 (PGE2) and C5a are briefly reviewed. It has been assumed for a long time that there were no reliable in vitro tests for that condition and that diagnostic confirmation can only be ascertained by provocation challenge. This appears no longer to be true, since several recent studies using a leukotriene release test (CAST) or a basophil activation test (BAT) on blood basophils, or a combination of both tests, yields positive results (70 - 75%) in a sizeable number of clinically validated cases, with a high specificity (above 85%). The finding in that syndrome of hyperreactive basophils suggests that the NSAID hypersensitivity syndrome is due to the associated effect of several factors : 1) Localized inflammatory processes causing a non specific cellular hyperreactivity; 2) An abnormal pharmacogenetic reaction to NSAIDs resulting in a hyperproduction of LTC4 and other mediators by activated mast cells, basophils and eosinophils.
引用
收藏
页码:3347 / 3358
页数:12
相关论文
共 179 条
[1]   Differential mediator release from basophils of allergic and non-allergic asthmatic patients after stimulation with anti-IgE and C5a [J].
Abrahamsen, O ;
Haas, H ;
Schreiber, J ;
Schlaak, M .
CLINICAL AND EXPERIMENTAL ALLERGY, 2001, 31 (03) :368-378
[2]   Validation of a flow cytometric assay detecting in vitro basophil activation for the diagnosis of muscle relaxant allergy [J].
Abuaf, N ;
Rajoely, B ;
Ghazouani, E ;
Levy, DA ;
Pecquet, C ;
Chabane, H ;
Leynadier, F .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 104 (02) :411-418
[3]   Anaphylatoxin C3a receptors in asthma [J].
Ali, H ;
Panettieri, RA .
RESPIRATORY RESEARCH, 2005, 6 (19)
[4]   ASPIRIN-SENSITIVE ASTHMA - ABNORMAL PLATELET RESPONSE TO DRUGS INDUCING ASTHMATIC ATTACKS - DIAGNOSTIC AND PHYSIOPATHOLOGICAL IMPLICATIONS [J].
AMEISEN, JC ;
CAPRON, A ;
JOSEPH, M ;
MACLOUF, J ;
VORNG, H ;
PANCRE, V ;
FOURNIER, E ;
WALLAERT, B ;
TONNEL, AB .
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1985, 78 (04) :438-448
[5]   Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma [J].
Antczak, A ;
Montuschi, P ;
Kharitonov, S ;
Gorski, P ;
Barnes, PJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (03) :301-306
[6]   Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases [J].
Asanuma, M ;
Miyazaki, I ;
Ogawa, N .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (06) :695-700
[7]   EFFECT OF SODIUM CROMOGLYCATE IN PREVENTING ASPIRIN INDUCED BRONCHOSPASM [J].
BASOMBA, A ;
ROMAR, A ;
PELAEZ, A ;
VILLALMANZO, IG ;
CAMPOS, A .
CLINICAL ALLERGY, 1976, 6 (03) :269-275
[8]   Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease [J].
Berges-Gimeno, MP ;
Simon, RA ;
Stevenson, DD .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (01) :180-186
[9]   The natural history and clinical characteristics of aspirin-exacerbated respiratory disease [J].
Berges-Gimeno, MP ;
Simon, RA ;
Stevenson, DD .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2002, 89 (05) :474-478
[10]   Hypersensitivity to nonsteroidal anti-inflammatory drugs and chronic urticaria cured by treatment of Blastocystis hominis infection [J].
Biedermann, T ;
Hartmann, K ;
Sing, A ;
Przybilla, B .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 146 (06) :1113-1114